Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination
with Pegaspargase and anlotinib in the treatment of stage IV NK/T-cell lymphoma patients
unfit for high-dose chemotherapy.